GD2 CAR T cells therapy(University College London)

N/A

Report date: 2023/08/17 20:03:08

Base Information

Drug NameGD2 CAR T cells therapy(University College London)
Drug Alias NameMulti-modular Chimeric Antigen Receptor Targeting GD2
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-GD2
TargetsDisialoganglioside GD2
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesUniversity College London
Inactive CompaniesN/A
Active IndicationsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A